Prostate Tetrapeptide Bioregulator
Prostamax is a prostate-specific tetrapeptide bioregulator that normalises the gene expression driving benign prostatic enlargement and chronic inflammation, improving urinary flow and reducing pelvic discomfort without altering testosterone or causing the sexual side effects of conventional treatments. Clinical data shows sustained improvements in prostate volume and voiding quality across multiple treatment cycles.
Product
Research shows
Practical product identifiers and format details for professional review.
Content
30 mg
Format
Injectable
Composition
10 mg/ml per ml
Prostamax penetrates prostate cell nuclei and binds to promoter regions regulating cell cycle control, inflammatory signalling, and secretory function in prostatic tissue. It normalises the proliferative signalling pathways that drive BPH, reduces prostatic inflammation through downregulation of NF-kB and COX-2 gene expression, and restores normal secretory protein synthesis in prostate gland cells. Research has documented reduced prostate volume, improved urinary flow rates, and reduction in chronic pelvic pain scores in men receiving repeated Prostamax courses as part of comprehensive prostate health protocols.
Based on published research and preclinical data. All benefits are documented under research-grade conditions.
Benign prostatic hyperplasia is driven by aberrant proliferative signalling in prostate stromal and epithelial cells. Prostamax normalises the gene expression patterns driving this hyperplasia: reducing abnormal cell cycle activation without the hormonal suppression used in conventional BPH pharmacotherapy.
By reducing the tissue volume and inflammation associated with BPH, Prostamax treatment has been associated with improved urinary flow rates, reduced nocturia, and improved voiding efficiency in Russian clinical studies: improvements in the quality-of-life parameters most affected by prostate enlargement.
Chronic prostatitis involves persistent NF-kB and COX-2 mediated inflammation in prostate tissue. Prostamax specifically downregulates these gene expression pathways in prostate cells, reducing the inflammatory burden that contributes to both chronic prostatitis and BPH progression.
Unlike standard BPH treatments (alpha-blockers, 5-alpha-reductase inhibitors), Prostamax does not alter testosterone, DHT, or other hormonal parameters. Its gene-regulatory mechanism is tissue-specific and avoids systemic hormonal effects, making it a complementary rather than competing approach.
Age-related changes in prostatic secretory protein production affect both fertility and urological health. Prostamax normalises secretory gene expression in prostate gland cells, supporting restoration of normal prostate function rather than merely suppressing symptoms.
Like other Khavinson bioregulators, Prostamax produces cumulative benefits with repeated 10-day courses across multiple cycles, with clinical improvements that persist beyond the active treatment period and deepen over consecutive protocol cycles.
Explore selected publications on Prostamax, with links to the original sources.
5 publications from the research library.
Evidence type
Publication and key finding
Source
Evidence type
Published research
Direct Prostamax evidence
Publication and key finding
The study reports that research goal was study of separate and joint influence of bioregulator prostamax and Cu(II) and Cd(II) ions on the chromatin structure in situ.
Georgian medical news
Evidence type
Published research
Direct Prostamax evidence
Publication and key finding
The study reports that a weak decrease in T(d)VIII and T(d)VII of lymphocytes treated with prostamax compared to untreated ones is connected with small structural changes of nucleosomal organization in the 10-nm filament and 30-nm-thick fiber.
Biofizika
Evidence type
Human clinical study
Research relevant to Prostamax
Publication and key finding
The study reports that hence, short peptides activate heterochromatin and heterochromatinized regions of cell chromosomes in senile subjects.
Bulletin of experimental biology and medicine
Evidence type
Preclinical study
Research relevant to Prostamax
Publication and key finding
The study reports that the peptide effective concentration of 0.05 ng/ml showed a stimulating effect in appropriate tissue cultures as compared to the control explants in all groups of rats.
Advances in gerontology = Uspekhi gerontologii
Evidence type
Published research
Research relevant to Prostamax
Publication and key finding
The study reports that prostamax changed the chromosomal parameters: 1) increased the frequency of SCE to 12,0±0,28 exchange in per cell (in intact cells - 5,9±0,2); 2) increased the frequency of Ag-positive NORs to 2.5 per cell (in intact cells - 0.95) 3) reduced in the frequency of.
Georgian medical news
Labbieux pens are designed for 30 to 31 administrations of 10 clicks. With daily use, this corresponds to approximately one month. We recommend starting with 5 clicks and building up to 10 clicks per administration. More sensitive people may use fewer clicks.
Before using our pens, consult the manual.
Prostamax shares the excellent safety profile of the Khavinson bioregulator family. No significant adverse effects have been documented in clinical research spanning decades. Injection site reactions are the most common observation. Unlike conventional BPH pharmacotherapy, Prostamax does not cause sexual dysfunction, orthostatic hypotension, or retrograde ejaculation: the side effects that frequently limit adherence to standard treatments. Its non-hormonal mechanism avoids the testosterone-related effects of 5-alpha-reductase inhibitors.
This public COA documents one selected production batch and is updated annually. It is not the COA for our latest available batch. Every batch has its own documentation, and partners can request the latest batch COA from our team.
Other products from the same range
